Vmn2r81 include a diverse set of compounds that can impede the function of this protein through various mechanisms by influencing signaling pathways with which Vmn2r81 is associated. Diphenhydramine, an H1 histamine receptor antagonist, can inhibit Vmn2r81 by reducing histamine signaling pathways that enhance Vmn2r81 activity. Similarly, quinidine can obstruct neuronal excitability by blocking voltage-gated sodium channels, thereby inhibiting signaling pathways involving Vmn2r81. Losartan, as an angiotensin II type 1 receptor blocker, can disrupt G-protein-coupled receptor activities, which may include those associated with Vmn2r81. Propranolol, a non-selective beta-blocker, can impede adrenergic signaling pathways that intersect with Vmn2r81's function.
Further, ondansetron can inhibit 5-HT3 serotonin receptors, reducing serotonergic signaling that could influence Vmn2r81 activity, while atropine can hinder cholinergic pathways in which Vmn2r81 may be involved by acting as a muscarinic acetylcholine receptor antagonist. Yohimbine can inhibit Vmn2r81 by blocking alpha-2 adrenergic receptors, affecting downstream signaling pathways. Tetrodotoxin, a potent inhibitor of voltage-gated sodium channels, can reduce neuronal activity, potentially reducing Vmn2r81 signaling involvement. Haloperidol can inhibit dopaminergic pathways where Vmn2r81 operates by antagonizing dopamine receptors. Nifedipine can impede signal transduction pathways involving Vmn2r81 by blocking L-type calcium channels. Amiloride can affect sodium balance and related signaling pathways, thereby disrupting pathways related to Vmn2r81. Lastly, mifepristone can act as a glucocorticoid receptor antagonist, disrupting glucocorticoid signaling pathways and potentially inhibiting the involvement of Vmn2r81. Each of these chemicals acts upon specific pathways or receptors, leading to an inhibition of the activities and processes in which Vmn2r81 is known to participate, without affecting the expression or modulation of the protein itself.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Quinidine | 56-54-2 | sc-212614 | 10 g | $102.00 | 3 | |
Blocks voltage-gated sodium channels, potentially inhibiting neuronal excitability and signaling pathways that Vmn2r81 may be involved in. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
Blocks angiotensin II type 1 receptors, potentially disrupting G-protein-coupled receptor activities, which may include Vmn2r81 signaling pathways. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
A non-selective beta-blocker that may inhibit adrenergic signaling pathways which could intersect with Vmn2r81 function. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $80.00 $326.00 | 1 | |
Inhibits 5-HT3 serotonin receptors, which may reduce serotonergic signaling that could indirectly influence Vmn2r81 activity. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $200.00 | 2 | |
Muscarinic acetylcholine receptor antagonist, possibly inhibiting cholinergic pathways that Vmn2r81 may be part of. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $50.00 $168.00 $520.00 | 2 | |
Blocks alpha-2 adrenergic receptors, potentially inhibiting downstream signaling pathways that may include Vmn2r81. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Dopamine receptor antagonist, potentially inhibiting dopaminergic pathways that Vmn2r81 may operate within. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Blocks L-type calcium channels, which may inhibit signal transduction pathways involving Vmn2r81. | ||||||
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $56.00 | 6 | |
Blocks epithelial sodium channels, potentially disrupting sodium balance and signaling pathways related to Vmn2r81. | ||||||
Mifepristone | 84371-65-3 | sc-203134 | 100 mg | $60.00 | 17 | |
Glucocorticoid receptor antagonist that may disrupt glucocorticoid signaling pathways, potentially inhibiting Vmn2r81 involvement. | ||||||